Taláb R - Search Results

1

[Proportion of tau protein to phosphorylated tau protein CSF levels in differential diagnosis of dementia].

Hort J, Valis M, Waberzinek G, Taláb R, Glossová L, Bojar M, Vyhnálek M, Skoda D, Masopust J, Stourac P. Hort J, et al. Among authors: talab r. Nervenarzt. 2008 Aug;79(8):891-2, 894-6, 898. doi: 10.1007/s00115-008-2501-7. Nervenarzt. 2008. PMID: 18626620 German.

2

Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients.

Valis M, Talab R, Stourac P, Andrys C, Masopust J. Valis M, et al. Among authors: talab r. Neuro Endocrinol Lett. 2008 Dec;29(6):971-6. Neuro Endocrinol Lett. 2008. PMID: 19112391

3

Abnormalities of tau-protein and beta-amyloid in brain ventricle cerebrospinal fluid.

Talab R, Valis M, Rehak S, Krejsek J. Talab R, et al. Neuro Endocrinol Lett. 2009;30(5):647-51. Neuro Endocrinol Lett. 2009. PMID: 20035270

4

Less frequent neurologic complications of anticoagulant therapy.

Taláb R, Waberzinek G. Taláb R, et al. Acta Medica (Hradec Kralove). 1999;42(4):147-50. Acta Medica (Hradec Kralove). 1999. PMID: 10812683

5

An electrophysiological study of visual processing in spinocerebellar ataxia type 2 (SCA2).

Kremlacek J, Valis M, Masopust J, Urban A, Zumrova A, Talab R, Kuba M, Kubova Z, Langrova J. Kremlacek J, et al. Among authors: talab r. Cerebellum. 2011 Mar;10(1):32-42. doi: 10.1007/s12311-010-0220-7. Cerebellum. 2011. PMID: 20927662

6

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Kappos L, Edan G, Freedman MS, Montalbán X, Hartung HP, Hemmer B, Fox EJ, Barkhof F, Schippling S, Schulze A, Pleimes D, Pohl C, Sandbrink R, Suarez G, Wicklein EM; BENEFIT Study Group. Kappos L, et al. Neurology. 2016 Sep 6;87(10):978-87. doi: 10.1212/WNL.0000000000003078. Epub 2016 Aug 10. Neurology. 2016. PMID: 27511182 Free PMC article. Clinical Trial.

7

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T. Preiningerova JL, et al. Among authors: talab r. CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101. CNS Neurosci Ther. 2013. PMID: 23607697 Free PMC article.

8

Marburg variant multiple sclerosis - a case report.

Talab R, Kundrata Z. Talab R, et al. Neuro Endocrinol Lett. 2011;32(4):415-20. Neuro Endocrinol Lett. 2011. PMID: 21876497

9

Natalizumab in the treatment of pediatric multiple sclerosis.

Talab R, Talabova M, Klzo L. Talab R, et al. Neuro Endocrinol Lett. 2012;33(6):579-89. Neuro Endocrinol Lett. 2012. PMID: 23160229

10

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Cree BAC, Cutter G, Wolinsky JS, Freedman MS, Comi G, Giovannoni G, Hartung HP, Arnold D, Kuhle J, Block V, Munschauer FE, Sedel F, Lublin FD; SPI2 investigative teams. Cree BAC, et al. Lancet Neurol. 2020 Dec;19(12):988-997. doi: 10.1016/S1474-4422(20)30347-1. Epub 2020 Oct 23. Lancet Neurol. 2020. PMID: 33222767 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page